Moleculin Biotech, Inc. (MBRX)

0.65 -5.66% (-0.04)

Over 1Y: -93.4%

2026-08-28
5 10
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Q3 '21 — Revenue: 0 Q3 '21 — Operating Cash Flow: -4.3M Q3 '21 — Free Cash Flow: -4.3M Q3 '21 — Net Income: -4.4M Q4 '21 — Revenue: 0 Q4 '21 — Operating Cash Flow: -4.3M Q4 '21 — Free Cash Flow: -4.3M Q4 '21 — Net Income: -2.8M Q1 '22 — Revenue: 0 Q1 '22 — Operating Cash Flow: -4.8M Q1 '22 — Free Cash Flow: -4.8M Q1 '22 — Net Income: -6.9M Q2 '22 — Revenue: 0 Q2 '22 — Operating Cash Flow: -8M Q2 '22 — Free Cash Flow: -8.1M Q2 '22 — Net Income: -6.8M Q3 '22 — Revenue: 0 Q3 '22 — Operating Cash Flow: -7.6M Q3 '22 — Free Cash Flow: -7.6M Q3 '22 — Net Income: -8.6M Q4 '22 — Revenue: 0 Q4 '22 — Operating Cash Flow: -7.3M Q4 '22 — Free Cash Flow: -7.3M Q4 '22 — Net Income: -6.8M Q1 '23 — Revenue: 0 Q1 '23 — Operating Cash Flow: -6M Q1 '23 — Free Cash Flow: -6M Q1 '23 — Net Income: -7.9M Q2 '23 — Revenue: 0 Q2 '23 — Operating Cash Flow: -5.1M Q2 '23 — Free Cash Flow: -5.1M Q2 '23 — Net Income: -6M Q3 '23 — Revenue: 0 Q3 '23 — Operating Cash Flow: -7.6M Q3 '23 — Free Cash Flow: -7.6M Q3 '23 — Net Income: -5.6M Q4 '23 — Revenue: 0 Q4 '23 — Operating Cash Flow: -4.9M Q4 '23 — Free Cash Flow: -5M Q4 '23 — Net Income: -10.3M Q1 '24 — Revenue: 0 Q1 '24 — Operating Cash Flow: -6.7M Q1 '24 — Free Cash Flow: -6.7M Q1 '24 — Net Income: -6.4M Q2 '24 — Revenue: 0 Q2 '24 — Operating Cash Flow: -5.9M Q2 '24 — Free Cash Flow: -6M Q2 '24 — Net Income: -6M Q3 '24 — Revenue: 0 Q3 '24 — Operating Cash Flow: -6.1M Q3 '24 — Free Cash Flow: -6.1M Q3 '24 — Net Income: -7M Q4 '24 — Revenue: 0 Q4 '24 — Operating Cash Flow: -5.1M Q4 '24 — Free Cash Flow: -5.1M Q4 '24 — Net Income: -6.6M Q1 '25 — Revenue: 0 Q1 '25 — Operating Cash Flow: -4.6M Q1 '25 — Free Cash Flow: -4.6M Q1 '25 — Net Income: -5.9M Q2 '25 — Revenue: 0 Q2 '25 — Operating Cash Flow: -5.6M Q2 '25 — Free Cash Flow: -5.6M Q2 '25 — Net Income: -17.8M Q3 '25 — Revenue: 0 Q3 '25 — Operating Cash Flow: -7.2M Q3 '25 — Free Cash Flow: -7.2M Q3 '25 — Net Income: -25.4M Q4 '25 — Revenue: 0 Q4 '25 — Operating Cash Flow: -5.4M Q4 '25 — Free Cash Flow: -5.4M Q4 '25 — Net Income: 15.6M Q1 '26 — Revenue: 0 Q1 '26 — Operating Cash Flow: -6.1M Q1 '26 — Net Income: -12.8M Q2 '26 — Revenue: 0 Q2 '26 — Operating Cash Flow: -6.7M Q2 '26 — Net Income: -7.6M -18M -9M 0 9M 18M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.5
ROIC -527.4%
Accruals -23.6%
ROA -143.8%
ROCE -245.2%
ROE -261.7%
Asset turnover —
Capex / sales —
EBITDA margin —
FCF margin —
Gross margin —
OCF / EBIT —
OCF margin —
OE margin —
Oper. margin —
Profit margin —
SBC / sales —

1 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

3.7
ND/EBITDA —
Current ratio 0.94×
Cash runway 0.29 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 0.94×
F-score 3.9 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

0.5
Shares change +761.4%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —
Sales/sh Y/Y —

0 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.